A Case of DPD Low Activity With Severe Fluorouracil Toxicity Caused by Uft/Uzel

Iwamoto, Akemi; Kawakami, Kiyoshi; Takemoto, Hiroyuki; Nishie, Hiroshi; Maeta, Michio

doi:10.3919/jjsa.71.2791

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, a total of 24 cases (including the present case) of severe adverse events were reported among patients with DPD deficiency who were treated with FPs, according to a search using PubMed and a domestic article search engine (3)(4)(5)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). The characteristics of these patients are summarized in Table 2.…”

Section: Discussionmentioning

confidence: 99%

Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Dihydropyrimidine dehydrogenase (DPD) deficiency induces severe adverse events in patients receiving fluoropyrimidines. We encountered a 64-year-old DPD-deficient man with a severe capecitabine-related gastrointestinal disorder. He received capecitabine-containing chemotherapy after rectal cancer resection. During the first course of chemotherapy, he developed severe diarrhea, a fever, and hematochezia. Endoscopy revealed mucosal shedding with bleeding throughout the gastrointestinal tract. DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells. After one month of intensive care, hemostasis and mucosal healing were noted, although his gastrointestinal function did not improve, and he had persistent nutritional management issues.

show abstract